Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver
Evonik is investing over CAD 150 million (EUR 93 million) to build a Good Manufacturing Practice (GMP)-compliant production site for lipid-based drugs in Vancouver, Canada. The project will be supported by up to CAD 68 million from the Canadian federal government’s Strategic Response Fund. This new facility is expected to significantly increase Evonik's capacity for developing and manufacturing lipid nanoparticles used in vaccines, therapeutics, and other advanced medicines. The site, set to launch production at the end of 2029, will more than triple current production capabilities and enhance quality control and microbiological testing. The investment aligns with Vancouver’s growing biotech ecosystem and strengthens Evonik's global presence in lipid-based drug delivery solutions.
Topics: GMP compliance government funding lipid-based drug delivery pharmaceutical manufacturing